|Other Names||Kallikrein-13, 3421-, Kallikrein-like protein 4, KLK-L4, KLK13, KLKL4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6332b was selected from the C-term region of human KLK13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Expressed in prostate, breast, testis and salivary gland|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. Expression of KLK13 is regulated by steroid hormones and may be useful as a marker for breast cancer.
Kapadia, C., et al., Biochem. Biophys. Res. Commun. 323(3):1084-1090 (2004).Petraki, C.D., et al., Prostate Cancer Prostatic Dis. 6(3):223-227 (2003).Chang, A., et al., Br. J. Cancer 86(9):1457-1464 (2002).Chang, A., et al., Anticancer Res. 21(5):3147-3152 (2001).Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).
If you have any additional inquiries please email technical services at email@example.com.